Upfront Darzalex Boosts PFS in Genetically High-Risk Myeloma

(MedPage Today) -- Patients with newly diagnosed or relapsed/refractory multiple myeloma with high-risk cytogenetics derived a progression-free survival (PFS) benefit from the addition of daratumumab (Darzalex) to a variety of backbone regimens...